Press coverage about Eyepoint Pharmaceuticals (NASDAQ:EYPT) has been trending somewhat negative this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eyepoint Pharmaceuticals earned a news sentiment score of -0.02 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 49.6364709773074 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:

A number of analysts recently issued reports on the company. Zacks Investment Research raised Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. HC Wainwright set a $3.00 price objective on Eyepoint Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 2nd. Finally, ValuEngine raised Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 29th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $4.90.

EYPT traded down $0.07 during trading on Friday, reaching $1.99. 276,754 shares of the company were exchanged, compared to its average volume of 513,700. The stock has a market capitalization of $118.87 million, a price-to-earnings ratio of -3.83 and a beta of 1.01. The company has a debt-to-equity ratio of 1.57, a quick ratio of 0.83 and a current ratio of 0.83. Eyepoint Pharmaceuticals has a 12-month low of $0.93 and a 12-month high of $2.88.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.

Featured Story: Book Value Of Equity Per Share – BVPS Explained

Insider Buying and Selling by Quarter for Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with's FREE daily email newsletter.